REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
02/04/2025
Back to search
Official data from USPTO
FREELINE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
02/04/2025
Trademark type
Combined
Nice classes
5, 40
Filing date
11/19/2018
Registration date
02/04/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/04/2020
Last transaction
02/04/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
99
Owner location
GB
Examiner
REGAN, BRENDAN
Law office
M40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the word "FREELINE" in stylised text.
Holders and representatives
Holders
Freeline Therapeutics Limited
Representatives
Samantha M. Quimby Frost Brown Todd LLC
Technical classification
Nice Classes
Class 5Class 40
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticalmedical and veterinary preparations for preventionamelioration or treatment of disordersnamely blood disorderslysosomal storage disordersmetabolic disordersinflammatory or immune system disordersautoimmune disordershepatological disorderscentral or peripheral nervous system disordersocular or ophthalmological disordersmuscular disordersmusculoskeletal disordersbone disorderscardiovascular or vascular disordersendocrine disordersgastrointestinal disordersneurological disordersdermatological disordersrespiratory disordersurological disorderscancers or infectious diseases; pharmaceuticalmedical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorderslysosomal storage disordersmetabolic disordersinflammatory or immune system disordersautoimmune disordershepatological disorderscentral or peripheral nervous system disordersocular or ophthalmological disordersmuscular disordersmusculoskeletal disordersbone disorderscardiovascular or vascular disordersendocrine disordersgastrointestinal disordersneurological disordersdermatological disordersrespiratory disordersurological disorderscancers or infectious diseases; pharmaceuticalmedical and clinical preparations for use in treatmentamelioration or prophylaxis of genetic or inherited or non-infectious diseases or disordersnamely blood disorderslysosomal storage disordersmetabolic disordersinflammatory or immune system disordersautoimmune disordershepatological disorderscentral or peripheral nervous system disordersocular or ophthalmological disordersmuscular disordersmusculoskeletal disordersbone disorderscardiovascular or vascular disordersendocrine disordersgastrointestinal disordersneurological disordersdermatological disordersrespiratory disordersurological disorders or cancers; pharmaceuticalmedical and clinical preparations for treatmentamelioration or prophylaxis of chronic or systemic diseasenamely blood disorderslysosomal storage disordersmetabolic disordersinflammatory or immune system disordersautoimmune disordershepatological disorderscentral or peripheral nervous system disordersocular or ophthalmological disordersmuscular disordersmusculoskeletal disordersbone disorderscardiovascular or vascular disordersendocrine disordersgastrointestinal disordersneurological disordersdermatological disordersrespiratory disordersurological disorders or cancers; pharmaceuticalmedical and clinical preparations for use in gene therapy for preventionamelioration or treatment of disordersnamely of blood disorderslysosomal storage disordersmetabolic disordersinflammatory or immune system disordersautoimmune disordershepatological disorderscentral or peripheral nervous system disordersocular or ophthalmological disordersmuscular disordersmusculoskeletal disordersbone disorderscardiovascular or vascular disordersendocrine disordersgastrointestinal disordersneurological disordersdermatological disordersrespiratory disordersurological disorderscancers or infectious diseases; pharmaceuticalmedical and clinical preparations for liver-targeted viral gene therapy; genetic medicines for preventionamelioration or treatment of disordersnamely blood disorderslysosomal storage disordersmetabolic disordersinflammatory or immune system disordersautoimmune disordershepatological disorderscentral or peripheral nervous system disordersocular or ophthalmological disordersmuscular disordersmusculoskeletal disordersbone disorderscardiovascular or vascular disordersendocrine disordersgastrointestinal disordersneurological disordersdermatological disordersrespiratory disordersurological disorderscancers or infectious disease; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; adeno-associated viral gene therapy preparations for preventionamelioration or treatment of disordersnamely blood disorderslysosomal storage disordersmetabolic disordersinflammatory or immune system disordersautoimmune disordershepatological disorderscentral or peripheral nervous system disordersocular or ophthalmological disordersmuscular disordersmusculoskeletal disordersbone disorderscardiovascular or vascular disordersendocrine disordersgastrointestinal disordersneurological disordersdermatological disordersrespiratory disordersurological disorderscancers or infectious diseases
Class 40
Pharmaceutical manufacturing and processing to the order and specification of others; biotechnological or biopharmaceutical manufacturing and processing to the order and specification of others; viral vector production to the order and specification of others; gene therapy manufacturing to the order and specification of others; pharmaceutical formulation to the order and specification of others
Publications
History of USPTO decisions and trademark events.
29 publications found
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
02/04/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/06/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/05/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/18/2020
FIMP
FINAL DISPOSITION PROCESSED
05/18/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/04/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
02/04/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/19/2019
PUBO
PUBLISHED FOR OPPOSITION
11/19/2019
GPNX
NOTIFICATION PROCESSED BY IB
11/15/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/30/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/30/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/30/2019
ALIE
ASSIGNED TO LIE
10/17/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/10/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/20/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/20/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/20/2019
RFNT
REFUSAL PROCESSED BY IB
04/06/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/21/2019
RFRR
REFUSAL PROCESSED BY MPU
03/21/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/12/2019
CNRT
NON-FINAL ACTION WRITTEN
03/11/2019
MAFR
APPLICATION FILING RECEIPT MAILED
03/08/2019
DOCK
ASSIGNED TO EXAMINER
03/04/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/04/2019
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
03/01/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/28/2019
Continuous trademark protection
Get notified about every new filing that threatens FREELINE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.